News round-up for 12-16 December by DDW Digital Content Editor Diana Spencer.
The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage melanoma and acute myeloid leukaemia.
The top stories:
Experimental immunotherapy has over 70% response rate
An immunotherapy that uses a new targeted approach to kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials.
New dermatitis treatment shows promising long-term results
A novel, patient-tailored monoclonal antibody therapy has shown promise in treating moderate to severe atopic dermatitis.
Novel peptide targets early molecular trigger of Alzheimer’s
A new study has demonstrated the ability of a novel peptide to selectively detect and neutralise an early molecular trigger of Alzheimer’s and other neurodegenerative diseases.
mRNA cancer vaccine meets primary efficacy endpoint
Personalised mRNA vaccine mRNA-4157/V940 has demonstrated a clinically meaningful improvement in patients with late-stage melanoma.
First AML patient successfully transplanted with investigational drug
Vor Bio has announced initial clinical data from VBP101, its Phase I/IIa study of tremtelectogene empogeditemcel or “trem-cel” in patients with acute myeloid leukaemia (AML).
